{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:31:00Z","timestamp":1768311060158,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T00:00:00Z","timestamp":1503100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1136\/annrheumdis-2017-211623","type":"journal-article","created":{"date-parts":[[2017,8,20]],"date-time":"2017-08-20T00:20:12Z","timestamp":1503188412000},"page":"2025-2030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project"],"prefix":"10.1016","volume":"76","author":[{"given":"Louise K","family":"Mercer","sequence":"first","affiliation":[]},{"given":"Anne C","family":"Regierer","sequence":"additional","affiliation":[]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[]},{"given":"William G","family":"Dixon","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Baecklund","sequence":"additional","affiliation":[]},{"given":"Karin","family":"Hellgren","sequence":"additional","affiliation":[]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[]},{"given":"Ren\u00e9","family":"Cordtz","sequence":"additional","affiliation":[]},{"given":"Kimme","family":"Hyrich","sequence":"additional","affiliation":[]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[]},{"given":"Angela","family":"Zink","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Canhao","sequence":"additional","affiliation":[]},{"given":"M Victoria","family":"Hernandez","sequence":"additional","affiliation":[]},{"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[]},{"given":"Jakub","family":"Zavada","sequence":"additional","affiliation":[]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[]},{"given":"Joachim","family":"Listing","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2017-211623_bib1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1136\/annrheumdis-2017-211623_bib2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1136\/annrheumdis-2017-211623_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype","volume":"98","author":"Smedby","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/annrheumdis-2017-211623_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.10939","article-title":"Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives","volume":"48","author":"Ekstr\u00f6m","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2017-211623_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","article-title":"Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211623_bib6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/art.40017","article-title":"Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?","volume":"69","author":"Hellgren","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211623_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211623_bib8","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2017-211623_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","article-title":"Risk of malignancy among patients with rheumatic conditions","volume":"88","author":"Thomas","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1136\/annrheumdis-2017-211623_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2017-211623_bib11","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","article-title":"Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases","volume":"14","author":"Salloum","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1136\/annrheumdis-2017-211623_bib12","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/MEG.0b013e32834bb90a","article-title":"Hepatosplenic T-cell lymphoma in patients receiving TNF-\u03b1 inhibitor therapy: expanding the groups at risk","volume":"23","author":"Parakkal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1136\/annrheumdis-2017-211623_bib13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211623_bib14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2017-211623_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1756-185X.12539","article-title":"Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan","volume":"17","author":"Chiu","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211623_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211623_bib17","first-page":"2016","article-title":"A R. Lymphoma in patients with Inflammatory Bowel Disease; a French nationwide observational cohort study","author":"Lemaitre M","year":"2016","journal-title":"UEGW"},{"key":"10.1136\/annrheumdis-2017-211623_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","article-title":"Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries","volume":"50","author":"Mariette","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2017-211623_bib19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10067-013-2303-6","article-title":"Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry","volume":"32","author":"Hor\u00e1k","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2017-211623_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/keq207","article-title":"Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0","volume":"50","author":"Carmona","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2017-211623_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"8","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1136\/annrheumdis-2017-211623_bib22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jbspin.2014.06.011","article-title":"Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register","volume":"81","author":"Sebastiani","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1136\/annrheumdis-2017-211623_bib23","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211623_bib24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2017-211623_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/279890","article-title":"Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt","volume":"2015","author":"Rom\u00e3o","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1136\/annrheumdis-2017-211623_bib26","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1136\/annrheumdis-2017-211623_bib27","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.11144","article-title":"Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma","volume":"48","author":"Baecklund","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2017-211623_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-\u03b1) inhibitors: results of the REFURBISH study","volume":"108","author":"Deepak","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/annrheumdis-2017-211623_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/aje\/kwv081","article-title":"Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma","volume":"182","author":"Hollander","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1136\/annrheumdis-2017-211623_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1136\/annrheumdis-2017-211623_bib31","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/art.27402","article-title":"Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis","volume":"62","author":"Hellgren","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724027286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724027286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2017-211623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:33:10Z","timestamp":1739521990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724027286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0003496724027286"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2017-211623","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2017-211623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 \u00a9 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}